Therapeutic area intelligence for Psoriatic Arthritis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

AbbVie →

Takeda →

Assets

Guselkumab →

Zasocitinib →

Recent signals(2)

ClinicalAugust 3, 2026

Study on Guselkumab Therapy's Impact on NAFLD in PsA Patients

The study investigates the effects of Guselkumab on disease severity in PsA patients with NAFLD.

ClinicalJune 21, 2026

Takeda initiates continuation study of Zasocitinib for Psoriatic Arthritis

Takeda is conducting a continuation study of Zasocitinib in adults with Psoriatic Arthritis to assess long-term safety and efficacy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Psoriatic Arthritis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.